Merck (BSP:MRCK34) Change In Payables And Accrued Expense : R$0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Merck Change In Payables And Accrued Expense?

Merck's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2023 was R$0 Mil. It means Merck's Accounts Payable & Accrued Expense stayed the same from Sep. 2023 to Dec. 2023 .

Merck's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was R$7,923 Mil. It means Merck's Accounts Payable & Accrued Expense increased by R$7,923 Mil from Dec. 2022 to Dec. 2023 .

Merck Change In Payables And Accrued Expense Historical Data

The historical data trend for Merck's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Change In Payables And Accrued Expense Chart

Merck Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-4,239.95

1,780.07

803.00

215.06

7,922.98

Merck Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Merck Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$0 Mil.

Merck Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Merck's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Merck (BSP:MRCK34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (BSP:MRCK34) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

MRK:USA MRK:Peru MRK:Mexico 1MRKX:Italy 6MKd:UK 0QAH:UK 6MK:Germany MRK:Chile MRK:Austria MRK:Argentina

Address

126 East Lincoln Avenue, Rahway, NJ, USA, 07065

Website

https://www.merck.com

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Merck (BSP:MRCK34) Headlines

No Headlines